Text Size

Stem Cell Transplant for Epidermolysis Bullosa

This study is currently recruiting participants.
Verified October 2012 by Masonic Cancer Center, University of Minnesota
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT01033552
First received: December 14, 2009
Last updated: October 26, 2012
Last verified: October 2012
History of Changes
  Purpose

This is an open-label, single institution, phase II study in patients with epidermolysis bullosa (EB). The underlying hypothesis is that the infusion of bone marrow or umbilical cord blood from a healthy unaffected donor will correct the collagen, laminin, integrin, or plakin deficiency and reduce the skin fragility characteristic of severe forms of EB. A secondary hypothesis is that mesenchymal stem cells from a healthy donor will enhance the safety and efficacy of the allogeneic hematopoietic stem cell transplant as well as serve as a source of renewable cells for the treatment of focal areas of residual blistering.


Condition Intervention Phase
Epidermolysis Bullosa
 Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Anti-thymocyte globulin
Drug: Cyclosporine A
Drug: Mycophenolate mofetil
Procedure: Hematopoietic stem cell transplant
Procedure: Mesenchymal stem cell transplant
Radiation: Total body irradiation
 Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Masonic Cancer Center, University of Minnesota:

Primary Outcome Measures:
  • Event-free survival [ Time Frame: 1 year and 2 Years Post-transplant ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incidence of transplant-related mortality (TRM) [ Time Frame: 180 Days Post Transplant ] [ Designated as safety issue: Yes ]
  • Pattern of biochemical improvement measured by increase in protein expression (collagen, laminin, integrin or plakin) [ Time Frame: Through 1 Year Post-Transplant ] [ Designated as safety issue: No ]
  • Quality of Life [ Time Frame: Pretreatment, Day 365 and Day 730 ] [ Designated as safety issue: No ]

Estimated Enrollment: 75
Study Start Date: January 2009
Estimated Study Completion Date: October 2019
Estimated Primary Completion Date: October 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Patients with Epidermolysis Bullosa
Patients with Epidermolysis Bullosa treated with chemotherapy regimen, bone marrow (BMT) or umbilical cord blood stem cell transplant (UCBSCT) and mesenchymal stem cell (MSC) transplant.
 Drug: Cyclophosphamide
50 mg/kg/day intravenously on Day -6.
Other Name: Cytoxan
Drug: Fludarabine
40 mg/m^2/day intravenously on Days -5, -4, -3 and -2.
Other Name: Fludara
Drug: Anti-thymocyte globulin
30 mg/kg on Days -4, -3 and -2.
Other Name: ATG
Drug: Cyclosporine A
Days -3 to 100+ to maintain a level of >200 ng/ml; initial dose 2.5 mg/kg over 2 hours every 8-12 hours for children.
Other Name: CSA
Drug: Mycophenolate mofetil
15 mg/kg intravenous twice per day on days -3 through 30.
Other Name: CellCept(R)
Procedure: Hematopoietic stem cell transplant
infused via intravenous drip on Day 0
Other Names:
  • Bone marrow transplant
  • Umbilical cord blood transplant
Procedure: Mesenchymal stem cell transplant
infused via intravenous drip on Day 0
Other Name: MSC
Radiation: Total body irradiation
200 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.

  Eligibility

Ages Eligible for Study:   up to 25 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of severe form of epidermolysis bullosa (EB) characterized by collagen, laminin, integrin, keratin or plakin deficiency. Assessment criteria for severe EB:

    • Severe blistering disease requiring dressings on >50% of the body surface area
    • Documented collagen, laminin, integrin, keratin or plakin deficiency (by immunofluorescence staining with protein specific antibodies or Western blotting and by mutation analysis)
    • Poor performance status as a result of EB (Lansky or Karnofsky <50%)

  • Adequate Organ Function Criteria

    • Renal: glomerular filtration rate > 60ml/min/1.73m2 patients aged ≤ 10 years
    • Hepatic: bilirubin, aspartate aminotransferase/alanine aminotransferase (AST/ALT), Alkaline phosphatase (ALP) < 5 x upper limit of normal
    • Pulmonary: oxygen saturation >92%
    • Cardiac: left ventricular ejection fraction ≥ 45%, normal electrocardiogram (EKG) or approved by Cardiology for transplant.
    • Performance status: ≥ 50% Lansky; ≥ 50% Karnofsky

  • Available Healthy HSC Donor (order of preference)

    • Related Donor (marrow or UCB)

      • HLA-A, B, C, DRB1 genotypic identical (sibling) donor
      • HLA-A, B, C, DRB1 phenotypic identical donor
      • 7/8 HLA matched donor at HLA-A, B, C, DRB1

    • Unrelated Donor

      • Marrow

        • HLA-A, B, C, DRB1 phenotypic identical donor
        • 7/8 HLA matched donor at HLA-A, B, C, DRB1
        • UCB
        • HLA-A, B (antigen level) and DRB1 (allele level) matched donor
        • 5/6 HLA matched donor at HLA-A, B, DRB1
        • 4/6 HLA matched donor at HLA-A, B, DRB1
  • Voluntary written consent

Exclusion Criteria:

  • Active systemic infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days).
  • History of human immunodeficiency virus (HIV) infection
  • Prior transplantation with donor skin
  • Evidence of squamous cell carcinoma
  • Donor has EB
  • Pregnancy or breast feeding. Females of child-bearing age must have a documented negative pregnancy test and agree to use contraception as a condition for enrollment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01033552

Contacts
Contact: Patricia Kleinke, RN 612-273-0857 pkleink1@fairview.org

Locations
United States, Minnesota
University of Minnesota Masonic Cancer Center and Medical Center Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Patricia Kleinke, RN     612-273-0857     pkleink1@fairview.org    
Principal Investigator: John E Wagner, MD            
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Investigators
Principal Investigator: John E. Wagner, MD Masonic Cancer Center, University of Minnesota
  More Information

No publications provided

Responsible Party: Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier: NCT01033552     History of Changes
Other Study ID Numbers: MT2009-09, 0911M74035
Study First Received: December 14, 2009
Last Updated: October 26, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Epidermolysis Bullosa
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous
Antilymphocyte Serum
Cyclophosphamide
Cyclosporins
Cyclosporine
Mycophenolate mofetil
Fludarabine monophosphate
Fludarabine
Mycophenolic Acid
 Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Enzyme Inhibitors
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents

ClinicalTrials.gov processed this record on May 23, 2013